Zonisamide NEW
| Price | $40 | $59 | $79 |
| Package | 50mg | 100mg | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Zonisamide | CAS No.: 68291-97-4 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Zonisamide |
| Description | Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate. |
| In vitro | Zonisamide inhibits monoamine oxidase B activity in vitro with an IC50 of 25 μM. |
| In vivo | Zonisamide inhibits monoamine oxidase B activity in vitro with an IC50 of 25 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (259.15 mM) |
| Keywords | parkinson’s disease | seizure | epilepsy | Carbonate dehydratase | AD-810 | Apoptosis | Inhibitor | cardiac hypertrophy | cardiac fibroblasts | inhibit | AD810 | Zonisamide | CI-912 | CI912 | Carbonic Anhydrase | NRCMs | SH-SY5Y |
| Inhibitors Related | Nisoldipine | Benzenesulfonamide | Phenytoin sodium | Cyclamic acid sodium | L-Ascorbic acid | Lidocaine | Lidocaine hydrochloride | L-Aspartic aicd sodium | Ethyl cinnamate | 1-Octanol |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | FDA-Approved Drug Library | Ion Channel Targeted Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-11-08 | |
| $0.00/1kg |
Zibo Wei Bin Import & Export Trade Co. Ltd.
|
2023-12-08 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2022-05-12 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-30 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-06-27 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY